The Role of NOS2 in Glaucoma
Author Information
Author(s): Libby Richard T, Howell Gareth R, Pang Iok-Hou, Savinova Olga V, Mehalow Adrienne K, Barter Joseph W, Smith Richard S, Clark Abbot F, John Simon WM
Primary Institution: The Jackson Laboratory
Hypothesis
Does NOS2 activity contribute to neurodegeneration in glaucoma?
Conclusion
NOS2 activity is not required for retinal ganglion cell death and associated axon degeneration in DBA/2J mice.
Supporting Evidence
- NOS2 expression levels varied during different stages of glaucoma.
- Genetic deficiency of Nos2 did not alter the IOP profile of DBA/2J mice.
- Neither Nos2 deficiency nor aminoguanidine treatment had any detectable effect on glaucomatous optic nerve damage.
Takeaway
This study found that a specific enzyme, NOS2, doesn't play a role in causing damage in a mouse model of glaucoma, meaning it might not be a good target for treatment.
Methodology
The study involved genetic and pharmacological manipulation of NOS2 in DBA/2J mice, assessing the incidence and severity of glaucoma through various experimental techniques.
Limitations
The study did not assess if other nitric oxide synthases could have compensated for the absence of NOS2.
Participant Demographics
DBA/2J mice, both male and female, were used in the study.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website